Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338244 · ClinicalTrials.gov registry record · Phase 4
Mortality Reduction After Oral Azithromycin Contingency: Mortality Study
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 66,228
- Enrollment target
NCT03338244 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 66,228 participants.
The verdict
NCT03338244, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66,228 participants
- Enrollment target
Study Summary
MORDOR was a cluster-randomized placebo controlled trial that assessed the efficacy of mass azithromycin distributions for the prevention of childhood mortality. All communities were subsequently treated with mass azithromycin for one year. The present trial re-randomized communities to azithromycin or placebo for the fourth and fifth year of the study.
Interventions
- DRUG Placebo
- DRUG Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66,228 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03338244
The ClinicalTrials.gov registry entry for NCT03338244 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66,228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03338244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03338244 about?
NCT03338244 is a clinical study titled "Mortality Reduction After Oral Azithromycin Contingency: Mortality Study". MORDOR was a cluster-randomized placebo controlled trial that assessed the efficacy of mass azithromycin distributions for the prevention of childhood mortality. All communities were subsequently treated with mass azithromycin for one year. The present trial re-randomized communities to azithromycin...
What is the current status of trial NCT03338244?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66,228 participants. The study started on 2017-10-20. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03338244?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).
Who is sponsoring clinical trial NCT03338244?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.